Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
CalciMedica, Inc. (NASDAQ:CALC) CEO Leheny A. Rachel reported purchasing 2,500 shares of common stock on July 14, 2025, at a price of $2.47 per share. The total value of the purchase was $6,175. The purchase comes as the stock shows strong momentum, with InvestingPro data revealing a 27% return over the past week. The company’s current market cap stands at $29.2 million.
Following the transaction, Leheny A. Rachel directly owns 130,926 shares. Additionally, 1,000 shares are held by spouse, 356,989 by Valence Investments SPV IV, LLC, 66,228 by Valence Investments SPV V, LLC and 316,109 by Valence Investments SPV VI, LLC. 2,500 shares are held by Scheibler-Leheny Family Living Trust. Analysts maintain a strong buy rating on the stock, with price targets ranging from $13 to $20. InvestingPro subscribers can access 8 additional key insights about CalciMedica’s financial health and growth prospects.
In other recent news, CalciMedica Inc. has detailed the design of its Phase 2 KOURAGE trial for Auxora, targeting acute kidney injury (AKI) with respiratory failure. The trial is set to enroll around 150 patients and aims to assess the effectiveness of Auxora in reducing the need for ventilator or dialysis support. CalciMedica highlighted preclinical data showing that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from a previous trial indicated a 62.7% reduction in mortality among COVID-19 patients with AKI who received Auxora compared to a placebo. In another development, CalciMedica has appointed Baker Tilly US, LLP as its new accounting firm following a merger with Moss Adams LLP. The transition was approved by the company’s Board of Directors’ Audit Committee, and no disagreements were reported regarding accounting practices with Moss Adams during the transition period. CalciMedica expects to have data from the KOURAGE trial by the end of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.